Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5936-5942

  Hsu, Ping I ^a   Wu, Deng Chyang ^b   Chen, Wen Chi ^a   Tseng, Hui Hwa ^a   Yu, Hsien Chung ^a   Wang, Huay Min ^a   Kao, Sung Shuo ^a   Lai, Kwok Hung ^a   Chen, Angela ^c   Tsay, Feng Woei ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d CHENG SHIU UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; ERADICATION THERAPY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING; AGED; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MIDDLE AGED; PATHOGENICITY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED;

EID: 84907429379     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02922-14     Document Type: Article

References (34)

1. Suerbaum S, Michetti P. 2002. Helicobacter pylori infection. N. Engl. J. Med. 347:1175-1186. http://dx.doi.org/10.1056/NEJMra020542.
2. Malfertheiner P, Chan EK, McColl KE. 2009. Peptic ulcer disease. Lancet 374:1449-1461. http://dx.doi.org/10J016/S0140-6736(09)6093S-7.
3. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Jr., Saeed ZA, Malaty HM. 1992. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized controlled study. Ann. Intern. Med. 116:705-708.
4. Sung JJ, Chung SC, Ling TK, Yung MY, Leung VK, Ng EK, Li MK, Cheng AF, Li AK. 1995. Antibacterial treatment of Gastric ulcer associated with Helicobacter pylori. N. Engl. J. Med. 332:139-142. http://dx.doi.org/10.1056/NEJM199501193320302.
5. Zucca E, Dreyling M, ESMO Guidelines Working Group. 2009. Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl 4): S113-S114. http://dx.doi.org/10.1093/annonc/mdp146.
6. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA, Second Asia-Pacific Conference. 2009. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 24:1587-1600. http://dx.doi.org/10.1111/j.1440-1746.2009.05982.x.
7. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K, Japanese Society for Helicobacter Research. 2010. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 15:1-20. http://dx.doi.org/10.1111/j.1523-5378.2009.00738.x.
8. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, The European Helicobacter Study Group (EHSG). 2012. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 61:646-664. http://dx.doi.org/10.1136/gutjnl-2012-302084.
9. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. 2007. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 102:1808-1825. http://dx.doi.org/10.1111/j.1572-0241.2007.01393.x.
10. Graham DY, Shiotani A. 2008. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat. Clin. Pract Gastroenterol. Hepatol. 5:321-331. http://dx.doi.org/10.1038/ncpgasthep1338.
11. Mégraud F. 2004. H. pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut 53:1374-1384. http://dx.doi.org/10-1136/gut.2003.022111.
12. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. 2010. Empiric quadruple vs triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am. J. Gastroenterol. 105:65-73. http://dx.doi.org/10.1038/ajg.2009.508.
13. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, Stella F, Di Leo A, Russo F, Marangi S, Monno R, Stoppino V, Morini S, Panella C, Ierardi E. 2006. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann. Intern. Med. 144:94-100. http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00006.
14. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. 2004. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. World J. Gastroenterol. 10:668-671.
15. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. 1998. One-week triple therapy using Omeprazole, Amoxycillin and Clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: Influence of dosage of Omeprazole and Clarithromycin. Aliment. Pharmacol. Ther. 12:383-388. http://dx.doi.org/10.1046/j.1365-2036.1998.00315.x.
16. De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, Stoppino G, Cea U, Pace A, Zotti M, Morini S, Panella C, Ierardi E. 2007. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J. Antimicrob. Chemother. 59: 783-785. http://dx.doi.org/10.1093/jac/dkm005.
17. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. 2007. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 56:1353-1357. http://dx.doi.org/30.3336/gut.2007.125658.
18. Essa AS, Kramer JR, Graham DY, Treiber G. 2009. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 14:109-118. http://dx.doi.org/10.1111/j.1523-5378.2009.00671.x.
19. Jafri NS, Hornung CA, Howden CW. 2008. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann. Intern. Med. 148:923-931. http://dx.doi.org/10.7326/0003-4819-148-12-200806170-00226.
20. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. 2007. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized trial. Ann. Intern. Med. 146:556-563. http://dx.doi.org/10.7326/0003-4819-146-8-200704170-00006.
21. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 2011. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial. Lancet 378:507-514. http://dx.doi.org/10.1016/S0140-6736(11)60825-8.
22. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS, Taiwan Helicobacter Consortium. 2012. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 381:205-213. http://dx.doi.org/10.1016/S0140-6736(12)61579-7.
23. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. 2010. Sequential and concomitant therapy with four drugs are equally effective for eradication of H. pylori infection. Clin. Gastroenterol. Hepatol. 8:36-41. http://dx.doi.org/10.1016/j.cgh .2009.09.030.
24. Hsu PI, Lai KH, Hsu PN, Lo GH, Yu HC, Chen WC, Tsay FW, Lin HC, Tseng HH, Ger LP, Chen HC. 2007. Helicobacter pylori infection and the risk of gastric malignancy. Am. J. Gastroenterol. 102:1-6. http://dx.doi.org/10.1111/j.1 572-0241.2007.01057.x.
25. Wu DC, Hsu PI, Tseng HH, Tsay FW, Lai KH, Kuo CH, Wang SW, Chen A. 2011. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore) 90:180-185. http://dx.doi.org/10.1097/MD .0b013e31821c9dlc.
26. Hsu PI, Wu DC, Wu JY, Graham DY. 2011. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter 16:146-152. http://dx.doi.org/10.1111/j.3523-5378.2011.00829.x.
27. Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS, Tsay FW, Wu CJ, Lo CC, Tseng HH, Yamaoka Y, Chen JL, Lo GH. 2005. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am. J. Gastroenterol. 100:2387-2392. http://dx.doi.Org/10.llll/j.1572-0241.2005.00264.x.
28. Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S. 2013. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: A randomized trial. J. Clin. Gastroenterol. 47:228-232. http://dx.doi.org/10.1097/MCG .0b013e31826015b0.
29. Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. 2012. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 17:282-285. http://dx.doi.Org/10.llll/j.3523-5378.2012.00953.x.
30. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. 2007. Meta-analysis: duration of first-line proton pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann. Intern. Med. 147:553-562. http://dx.doi.org/T0.7320/0003-483 9-147-8-200710160-00008.
31. Ford A, Moayyedi P. 2003. How can the current strategies for Helicobacter pylori eradication be improved? Can. J. Gastroenterol. 17(Suppl B):36-40.
32. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F, Pylera Study Group. 2011. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial. Lancet 377:905-913. http://dx.doi.org/10.1016/S0140-6736(11)60020-2.
33. Hsu PI, Wu DC, Wu JY, Graham DY. 2011. Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 16:139-145. http://dx.doi.org/10.1111/j.1523-5378.2011.00828.x.
34. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. 2013. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: A prospective randomized trial. Helicobacter 18: 129-134. http://dx.doi.org/10.1111/hel.12017.